

FINAL DIRECTOR'S INTEREST NOTICE

20 January 2020 – Leading medical cannabis pharmaceutical company **AusCann Group Holdings Limited** (ASX: AC8) (AusCann or 'the Company') advises that as part of the AusCann Board renewal process announced in October 2019, Hon. Cheryl Edwardes AM has retired as a Director of the Company, effective from 19 January 2020. As announced in December 2019, Mr Max Johnston has now assumed the role of Chairman of AusCann.

AusCann CEO, Mr Ido Kanyon commented "Cheryl's extensive regulatory and commercial experience, combined with her energy and enthusiasm for breaking new ground in the establishment of cannabinoid medicines as a legitimised patient treatment has been invaluable to AusCann as a first mover in a new medical industry."

AusCann incoming Chairman, Mr Max Johnston, added "I want to express my sincere appreciation to the professional and independent counsel Cheryl gave to the Board and the integral role she played during the Board renewal process since October. On behalf of the Board, I would also like to thank Cheryl for the significant role she performed over the past three years in establishing AusCann as a leading cannabinoid focused pharmaceutical company. We wish Cheryl all the very best for the future."

A final Director's Interest Notice for Mrs Edwardes is attached.

ENDS

This ASX announcement was authorised for release by the Chairman, Mr Max Johnston and Company Secretary, Ms Susan Hunter.

For more information, please contact:

For Investment Enquiries

Quentin Megson
Chief Financial Officer
info@auscann.com.au
+61 8 9561 8834

For Media Enquiries

Elodie Castagna
FTI Consulting
elodie.castagna@fticonsulting.com
+61 8 9321 8533

ABOUT AUSCANN

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based pharmaceutical company focused on the development, production, and distribution of cannabinoid-based medicines within Australia and internationally. AusCann transforms the way Medicinal Cannabis is dispensed today by making standardised dose-controlled cannabinoid-based pharmaceutical products and clinical evidence accessible to patients, physicians and healthcare providers. AusCann enables physicians to treat their patients with a reliable, stable and standardised cannabinoid-based pharmaceutical product, monitor treatment results and adjust treatment algorithms using a portfolio of products and formulations.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity AusCann Group Holdings Ltd
ABN 72 008 095 207

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Hon. Cheryl Edwardes AM
Date of last notice	24 January 2017
Date that director ceased to be director	19 January 2020

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities 50,000 fully paid ordinary shares.

+ See chapter 19 for defined terms.

Appendix 3Z Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	-

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.